-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

Benzinga·10/08/2026 20:59:02
Diffusion vocale
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.